Transgender health: Hormone therapy may raise risk of CV events
This week, apixaban edges out other DOACs for octogenarians, methotrexate fails to cut cardiovascular events in a large trial, withdrawing heart failure medications after recovery leads to relapse, and showing patients their own atherosclerosis may reduce their cardiovascular event risk.
Subscribe to Cardiocast wherever you get your podcasts.Amazon AlexaApple Podcasts
We noticed you have an ad blocker enabled. Please whitelist us so we can continue to provide free content.